Pottayil G Sasikumar
Overview
Explore the profile of Pottayil G Sasikumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sasikumar P, Ramachandra M
Front Immunol
. 2022 May;
13:752065.
PMID: 35585982
Pioneering success of antibodies targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has changed the outlook of cancer therapy. Although these...
2.
Sasikumar P, Sudarshan N, Adurthi S, Ramachandra R, Samiulla D, Lakshminarasimhan A, et al.
Commun Biol
. 2021 Jun;
4(1):699.
PMID: 34103659
Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due to their shorter pharmacokinetic exposure...
3.
Sasikumar P, Ramachandra R, Adurthi S, Dhudashiya A, Vadlamani S, Vemula K, et al.
Mol Cancer Ther
. 2019 Apr;
18(6):1081-1091.
PMID: 31015307
Pioneering success of antibodies targeting immune checkpoints such as PD-1 and CTLA4 has opened novel avenues for cancer immunotherapy. Along with impressive clinical activity, severe immune-related adverse events (irAE) due...
4.
Sasikumar P, Ramachandra M
BioDrugs
. 2018 Sep;
32(5):481-497.
PMID: 30168070
Advances in harnessing the immune system for cancer treatment have been spectacular in recent years as witnessed by the approval of a number of antibodies targeting the PD-1/PD-L1 immune checkpoint...
5.
Sasikumar P, Ramachandra M
Future Med Chem
. 2017 Aug;
9(12):1305-1308.
PMID: 28771036
No abstract available.
6.
Shindo Y, McDonough J, Chang K, Ramachandra M, Sasikumar P, Hotchkiss R
J Surg Res
. 2016 Dec;
208:33-39.
PMID: 27993215
Background: Sepsis remains a leading cause of death in most intensive care units. Many deaths in sepsis are due to nosocomial infections in patients who have entered the immunosuppressive phase...
7.
Pedersen S, Sasikumar P, Chelur S, Holst B, Artmann A, Jensen K, et al.
J Pept Sci
. 2010 Sep;
16(11):664-73.
PMID: 20853314
The prevalence of obesity is increasing with an alarming rate worldwide and there is a need for efficacious satiety drugs. PYY3-36 has been shown to play a role in hypothalamic...
8.
Pedersen S, Sasikumar P, Vrang N, Jensen K
ChemMedChem
. 2010 Feb;
5(4):545-51.
PMID: 20183851
The gut hormone PYY3-36 influences food intake and body weight via interaction with hypothalamic presynaptic Y2 receptors (Y2R). Novel Y2R-selective analogues of PYY3-36 are therefore potential drug candidates for the...